

June 16, 2016



## **AxoGen to Present at JMP Securities Healthcare Conference 2016**

**ALACHUA, FL – June 16, 2016** – AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter J. Mariani, Chief Financial Officer, will present at JMP Securities Healthcare Conference 2016 in New York City at the St. Regis Hotel. The presentation is scheduled for Tuesday, June 21, 2016 at 3:30 pm ET (12:30 pm PT).

The presentation will be webcast live and can be accessed through the Investors page at [www.axogeninc.com](http://www.axogeninc.com). For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on [www.axogeninc.com](http://www.axogeninc.com).

### **About AxoGen**

AxoGen (AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouch™ Two-Point Discriminator and AcroVal™ Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function.

### **Contacts:**

AxoGen, Inc.  
Peter J. Mariani, Chief Financial Officer  
386.462.6856  
[InvestorRelations@AxoGenInc.com](mailto:InvestorRelations@AxoGenInc.com)

The Trout Group – Investor Relations  
Brian Korb  
646.378.2923  
[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)